evopointbio.comCrawled Oct 29, 2026
信诺维 develops drugs for oncology, infectious diseases, and metabolic disorders using a platform that includes targeted therapies, antibody-drug conjugates, and molecular glues/protein degraders. Its pipeline includes 10 candidates in clinical trials and over 10 in preclinical stages.
Suzhou Sinovent Pharmaceuticals completes its listing on Shanghai’s STAR Market, securing a **$2.5 billion valuation** after raising **$247.5 million** in its IPO. The biotech firm priced shares at **$3.80** and closed its first trading day at **$5.52**, reflecting strong investor demand. The company specializes in respiratory disease treatments and vaccine development.
Sep 2026dealroom.coNews article
Evopoint Biosciences shifts **10% of its post-strategic IPO shares** from offline to online allocations due to **high demand during the online subscription phase** in Shanghai’s STAR market. The biotech firm’s IPO garners significant investor interest, prompting the adjustment to accommodate broader participation. The move reflects strong early engagement with the offering.
Sep 2026MarketScreenerNews article
Evopoint Biosciences raises **1.8 billion yuan** through its **Shanghai STAR Market IPO**, pricing **65.3 million shares** at **27.60 yuan each**, representing **15% of its post-IPO share capital**. The biotech firm leverages the offering to expand its operations in precision medicine and diagnostics. The transaction marks a significant milestone for the company’s growth in China’s capital markets.
Sep 2026MarketScreenerNews article
Evopoint Biosciences submits a **Pre-NDA** to China’s **NMPA** for its **funobactam-imipenem-cilastatin** combination, a **β-lactam/β-lactamase inhibitor (BL/BLI)** targeting **carbapenem-resistant Gram-negative bacteria (CRO)**. The drug candidate, if approved, would mark the **first globally** with broad-spectrum activity against three critical resistant strains. The submission covers Evopoint’s **Category 1 product**, positioning it as a potential breakthrough in treating multi-drug-resistant infections.
Dec 2024Insight, China's Pharmaceutical IndustryNews article
